Skip to main content

Market Overview

HC Wainwright Initiates Stemline Therapeutics At Buy

Share:

In a report published Monday, H.C. Wainwright analysts initiated coverage of Stemline Therapeutics Inc (NASDAQ: STML) with a Buy rating and a price target of $38.

Stemline Therapeutics is an emerging player in the biotechnology filed and is focusing on the development of novel anti-cancer therapeutics that eradicate both the tumor bulk and the cancer stem cells.

"In our view, Stemline represents a unique investment opportunity in the small-cap oncology space due to its rapidly advancing clinical-stage pipeline and the proprietary development platform in cancer stem cells (CSCs).Accelerated approval pathway," the analysts stated.

The company's lead drug candidate, SL-401, is risk-mitigated from a clinical as well as regulatory perspective.

"Considering the orphan drug designation from the FDA, and the survival-enhancing efficacy demonstrated in clinical trials thus far, we believe SL-401 is likely to produce positive results in 2015 from the ongoing Phase 2 lead-in study in BPDCN. We think SL-401 could secure approval on the basis of a single, randomized, open-label pivotal study enrolling 40-45 BPDCN patients, which is scheduled to initiate in 2H 2015," the analysts added.

Stemline's second candidate SL-701, an immunotherapy with orphan drug designation for brain cancer, has previously demonstrated anti- tumor efficacy in both adult and pediatric patients. "We believe this drug could report initial data from the ongoing Phase 2 second-line adult GBM study in 2015, and may be eligible for accelerated approval," the report stated.

Apart from the company's focus on cancer stem cells, several major near-term catalysts for the company include the announcement of data from its ongoing BPDCN led-in-study in 2015 and the initiation of a pivotal trial for BPDCN by end-2015.

"Stemline is one of the most attractive development-stage oncology-focused firms, given its potential for an accelerated path to market for niche indications, and its technology and pipeline targeting CSCs," the analysts wrote.

Latest Ratings for STML

DateFirmActionFromTo
May 2020WedbushDowngradesOutperformNeutral
May 2020Ladenburg ThalmannDowngradesBuyNeutral
May 2020HC Wainwright & Co.DowngradesBuyNeutral

View More Analyst Ratings for STML
View the Latest Analyst Ratings

 

Related Articles (STML)

View Comments and Join the Discussion!

Posted-In: H.C. WainwrightAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
GOOGLMizuhoMaintains2,600.0
VZIOWells FargoInitiates Coverage On31.0
TWTROppenheimerMaintains85.0
SBUXOppenheimerMaintains135.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com